A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Articolo
Data di Pubblicazione:
2020
Citazione:
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study / Carlo-Stella, C.; Delarue, R.; Scarfo', L.; Barde, P. J.; Nair, A.; Locatelli, S. L.; Morello, L.; Magagnoli, M.; Vakkalanka, S.; Viswanadha, S.; Ferreri, A. J. M.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 20:2(2020), pp. 78-86. [10.1016/j.clml.2019.10.013]
Abstract:
Tenalisib (RP6530) is a novel, highly specific dual phosphoinositide-3 kinases (PI3K) δ/γ inhibitor with nano-molar potency. It demonstrated acceptable safety up to 1200 mg twice a day with no dose-limiting toxicities in patients with relapsed/refractory hematologic malignancies. Consistent clinical response was seen at doses 200 mg and above. Further phase I/II studies are being undertaken to evaluate efficacy across different histologies.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Dose escalation; Dose limiting toxicity; pAKT; Phase I; Tumor microenvironment
Elenco autori:
Carlo-Stella, C.; Delarue, R.; Scarfo', L.; Barde, P. J.; Nair, A.; Locatelli, S. L.; Morello, L.; Magagnoli, M.; Vakkalanka, S.; Viswanadha, S.; Ferreri, A. J. M.
Link alla scheda completa:
Pubblicato in: